Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $20.50

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average recommendation of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $20.50.

A number of brokerages have recently issued reports on KROS. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Leerink Partners decreased their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Finally, Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the transaction, the insider directly owned 27,559 shares in the company, valued at approximately $283,582.11. This represents a 11.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,893 shares of company stock valued at $60,507 in the last ninety days. Insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System boosted its stake in Keros Therapeutics by 72.6% during the second quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after acquiring an additional 1,148 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Keros Therapeutics during the second quarter valued at about $90,000. Finally, PDT Partners LLC bought a new position in shares of Keros Therapeutics during the 2nd quarter worth about $122,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $11.32 on Friday. The firm has a market capitalization of $224.48 million, a PE ratio of -3.06 and a beta of 1.01. The business’s 50-day moving average price is $10.81 and its two-hundred day moving average price is $11.37. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.